NCT05863442View on ClinicalTrials.gov

Comparative PK, Safety, Tolerability, Immunogenicity, and PD Profile Study of TUR03 and Soliris in Healthy Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 10, 2023

Primary Completion Date

July 23, 2024

Study Completion Date

October 5, 2024

Conditions
Healthy
Interventions
DRUG

Soliris 300 MG in 30 ML Injection

Active Comparator

DRUG

TUR03 300 MG in 30 ML Injection

Investigational medicinal Product, eculizumab - Turgut

Trial Locations (1)

Unknown

RECRUITING

Q-Pharm Pty Limited, Herston

All Listed Sponsors
lead

Turgut Ardika PTY LTD

INDUSTRY